Smoldering multiple myeloma: a multi-country mixed-methods study on disease perceptions and patient treatment preferences

Résumé fourni par la source

To understand disease perceptions and treatment preferences of patients with high-risk smoldering multiple myeloma (HR-SMM) or multiple myeloma (MM) that recently progressed from HR-SMM, and to estimate the minimum progression-free survival (min-PFS) required to accept the treatment burden. This mixed-methods study interviewed 50 patients (HR-SMM and MM 1:1) from the USA, France, Italy, and Spain. Qualitative semi-structured interviews explored symptoms, quality of life, and awareness and expectations of SMM treatments. A quantitative thresholding exercise elicited the min-PFS for patients to accept a hypothetical treatment. Results were reported for HR-SMM and MM. The most common symptoms were fatigue (68%) and pain (56%); 20% were asymptomatic. Most treatment-naïve patients (n = 31/44) accepted physician recommendations that treatment was not needed, burdensome, or not available. Twenty-three patients (61%) were willing to start treatment while having HR-SMM. Patients expected treatments to delay disease progression (30%) or increase life expectancy (24%), whereas 22% expected to be “cured” if treated. The min-PFS for the given treatment was 60 months; 61 and 59 months for HR-SMM and MM, respectively. Considerable psychological, physical, and functional burdens were imposed on HR-SMM patients by potential disease progression. Most patients were willing to receive treatment to delay progression and reduce symptomatic burden.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.